HAE
Haemonetics·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Beats Expectation
Bullish Abandoned Baby
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HAE
Haemonetics Corporation
A global healthcare company focused on the fields of blood and plasma component collection, the surgical suite, and hospital transfusion services
Healthcare Equipment and Supplies
--
05/10/1991
New York Stock Exchange
3,023
03-31
Common stock
125 Summer Street, 02110, Boston, Massachusetts
--
Haemonetics Corporation was incorporated in 1971 under the laws of Massachusetts, It is a global medical device company dedicated to providing innovative blood management solutions to customers — plasma source collectors, blood collection institutions and hospitals. It has a strong brand advantage in medical device systems in the blood transfusion industry. While providing solutions to customers, it also provides information technology platforms and value-added services. Its solutions help patients improve clinical outcomes and increase supply chain efficiency in blood.
Earnings Call
Q4/2025
Estimate EPS1.22
Actual EPS1.24
Estimate Revenue329.38M
Actual Revenue331.00M
Haemonetics' Q4 2025 Earnings Call: Discrepancies in Plasma Growth, Vascular Closure Expectations, and Margin Projections
May 20,2025 12:21
Earnings Decrypt
Earnings Decrypt
Q1/2026
Estimate EPS1.02
Actual EPS1.1
Estimate Revenue304.61M
Actual Revenue321.39M
Haemonetics' Q1 2026 Earnings Call: Key Contradictions in Plasma Growth, Margins, and Competitive Strategy
Aug 08,2025 12:47
Earnings Decrypt
Earnings Decrypt
Q2/2026
Estimate EPS1.11
Actual EPS1.27
Estimate Revenue311.49M
Actual Revenue327.00M
Haemonetics Q2 2026: Contradictions Emerge on Plasma Collections, IVT Turnaround, and VASCADE Strategy
Nov 07,2025 03:50
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
HAE has released its 2026 Q2 earnings. EPS was reported at 1.27, versus the expected 1.11, beating expectations. The chart below visualizes how HAE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HAE has released its 2026 Q2 earnings report, with revenue of 327.31M, reflecting a YoY change of -5.27%, and net profit of 38.68M, showing a YoY change of 14.34%. The Sankey diagram below clearly presents HAE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
